Mark Jeffrey Delong Sells 3,371 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Mark Jeffrey Delong sold 3,371 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $73,386.67. Following the transaction, the insider owned 78,353 shares of the company’s stock, valued at $1,705,744.81. This represents a 4.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Mark Jeffrey Delong also recently made the following trade(s):

• On Tuesday, January 20th, Mark Jeffrey Delong sold 1,334 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $19.79, for a total transaction of $26,399.86.
• On Tuesday, January 13th, Mark Jeffrey Delong sold 1,780 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $22.19, for a total transaction of $39,498.20.

Apellis Pharmaceuticals Stock Performance

Shares of APLS traded down $0.25 during mid-day trading on Friday, reaching $21.76. 2,214,978 shares of the company’s stock traded hands, compared to its average volume of 3,258,745. Apellis Pharmaceuticals, Inc. has a 12 month low of $16.10 and a 12 month high of $30.91. The stock has a market capitalization of $2.75 billion, a P/E ratio of 70.18 and a beta of 0.31. The business’s 50-day moving average price is $22.99 and its 200-day moving average price is $23.49. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The company had revenue of $458.58 million during the quarter, compared to analysts’ expectations of $364.58 million. During the same quarter in the prior year, the business posted ($0.46) earnings per share. The company’s revenue for the quarter was up 133.0% compared to the same quarter last year. Equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

More Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re‑rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near‑term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Wells Fargo & Company lowered their price objective on shares of Apellis Pharmaceuticals from $29.00 to $26.00 and set an “overweight” rating on the stock in a research note on Tuesday. Stifel Nicolaus lowered their price target on Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, December 19th. Cantor Fitzgerald dropped their price objective on Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 13th. Needham & Company LLC cut their price objective on Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday, January 13th. Finally, William Blair reaffirmed an “outperform” rating on shares of Apellis Pharmaceuticals in a report on Monday, December 15th. Twelve analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $33.53.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. PNC Financial Services Group Inc. boosted its position in shares of Apellis Pharmaceuticals by 0.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 58,856 shares of the company’s stock valued at $1,019,000 after purchasing an additional 465 shares during the period. Wedmont Private Capital raised its holdings in Apellis Pharmaceuticals by 4.1% during the 4th quarter. Wedmont Private Capital now owns 11,883 shares of the company’s stock worth $315,000 after buying an additional 468 shares during the period. Amalgamated Bank raised its holdings in Apellis Pharmaceuticals by 6.9% during the 3rd quarter. Amalgamated Bank now owns 8,674 shares of the company’s stock worth $196,000 after buying an additional 563 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Apellis Pharmaceuticals by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock valued at $84,000 after buying an additional 655 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of Apellis Pharmaceuticals by 80.0% during the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after acquiring an additional 855 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.